ChemoCentryx, Inc. (CCXI) Sets 52-Week High; Strong Momentum for Holders

March 21, 2018 - By Henry Gaston

Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.26, from 1.4 in 2017Q2. It fall, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported.
Proshare Advisors Lc holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 29,111 shares. Legal & General Grp Public Limited Co reported 5,113 shares or 0% of all its holdings. Los Angeles Cap Mgmt And Equity has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Schwab Charles Invest Mgmt Inc has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 35,200 shares. Rhumbline Advisers reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Bnp Paribas Arbitrage accumulated 2,159 shares. Jacobs Levy Equity Management reported 0.02% stake. 35,991 were accumulated by American Century Incorporated. State Of Wisconsin Board invested in 0% or 19,000 shares. Morgan Stanley holds 0% or 91,749 shares in its portfolio. Bridgeway Cap Management invested in 53,046 shares or 0% of the stock. Federated Invsts Pa, Pennsylvania-based fund reported 64,610 shares. Paw Cap holds 160,000 shares. Barclays Public Ltd Company holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 1,765 shares. Arrowstreet Ltd Partnership holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 17,999 shares.

The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) hit a new 52-week high and has $15.92 target or 7.00 % above today’s $14.88 share price. The 6 months bullish chart indicates low risk for the $727.71 million company. The 1-year high was reported on Mar, 21 by If the $15.92 price target is reached, the company will be worth $50.94 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 4.31% or $0.62 during the last trading session, reaching $14.88. About 164,519 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since March 21, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on May, 9. They expect $-0.19 EPS, down 58.33 % or $0.07 from last year’s $-0.12 per share. After $0.80 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -123.75 % negative EPS growth.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. ChemoCentryx has $16 highest and $1300 lowest target. $14.50’s average target is -2.55% below currents $14.88 stock price. ChemoCentryx had 6 analyst reports since September 3, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 8 by Cowen & Co. The firm has “Sell” rating given on Monday, September 21 by Zacks. JMP Securities maintained it with “Buy” rating and $1300 target in Thursday, August 10 report. The firm has “Overweight” rating given on Tuesday, March 13 by JP Morgan. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Sell” rating by Zacks on Thursday, September 3. The stock has “Mkt Outperform” rating by JMP Securities on Tuesday, February 21.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $727.71 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 41.32 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.